Perampanel for adjunctive treatment of partial-onset seizures: A pooled dose-response analysis of phase III studies

Epilepsia

Volumn 55, Issue 3, 2014, Pages 423-431

  Kramer, Lynn D ^a   Satlin, Andrew ^a   Krauss, Gregory L ^b   French, Jacqueline ^c   Perucca, Emilio ^d   Ben Menachem, Elinor ^e   Kwan, Patrick ^f   Shih, Jerry J ^g   Laurenza, Antonio ^a   Yang, Haichen ^a   Zhu, Jin ^a   Squillacote, David ^a  

^a EISAI INC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g MAYO CLINIC   (United States)

Author keywords

Actual (last) dose; Antiepileptic; Efficacy; Epilepsy; amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid

Indexed keywords

PERAMPANEL; PLACEBO;

ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FALLING; FATIGUE; HEADACHE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SOMNOLENCE;

ACTUAL (LAST) DOSE; ANTIEPILEPTIC; EFFICACY; EPILEPSY; Α-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID;

ADULT; ANTICONVULSANTS; COHORT STUDIES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896393129     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12527     Document Type: Article

References (13)

1. Rogawski MA, Donevan SD,. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv Neurol 1999; 79: 947-963.
2. Rogawski MA,. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11: 56-63.
3. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012; 125: 8-15.
4. Fuseau E, Templeton D, Hussein Z,. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr 2011; 11 (Suppl. 1):abs 1.264.
5. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79: 589-596.
6. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013; 54: 117-125.
7. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78: 1408-1415.
8. Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013; 54: 1481-1489.
9. Ko D, Ramsay RE,. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013; 197: 36-43.
10. Gidal BE, Majid O, Hussein Z,. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 2013; 54: 1490-1497.
11. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 2013; 54: 126-134.
12. Kramer L, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: a dose-response analysis from phase III studies. Neurology 2012; 78:(Meeting Abstracts 1): abs P06.117.
13. Laurenza A, Ferry J, Hussein Z,. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr 2012; 12 (Suppl. 1):abs 2.231.